Progress in Alzheimer’s Disease Builds Renewed Interest in Research
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen…
Rigsby RigsbyOctober 27, 2021
Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer’s Disease
The NTG brought together a national panel of expert researchers and practitioners in the field…
A New Perspective on The Aduhelm Controversy
In June, the FDA granted “accelerated approval” to Biogen’s Aduhelm drug. This is the first…
Rigsby RigsbyOctober 15, 2021
Aging and Alzheimer’s Disease Webinar
The video below is a recording of a webinar presented by Brian Chicoine, MD and…
Capetivate capetivateSeptember 29, 2021
Aging and Alzheimer’s Disease
This document contains the slides from a webinar on aging and Alzheimer's disease in presented…
Capetivate capetivateSeptember 29, 2021
Psychoses, Depression, Behavioral Changes, Family Support, Medications
Question: My 57-year-old brother has hallucinations and delusions. What can be done for this? He's…
Capetivate capetivateAugust 12, 2021
Research in Down syndrome Associated Alzheimer’s disease: What do we know and where are we going?
In this webinar, Dr. Hendrix will discuss this important milestone in Alzheimer’s disease research and…
Capetivate capetivateJune 18, 2021
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study
With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However,…
Capetivate capetivateApril 30, 2021